What You Missed
The global ASIT community reunited to accelerate end-to-end therapeutic innovation and share the latest progress advancing antigen-specific immune tolerance. Following a year of breakthrough developments including late-stage readouts in type 1 diabetes and peanut allergy, new mRNA-LNP tolerance platforms, and emerging gene and cell-based tolerance strategies, momentum is building rapidly.
As ASIT R&D translates into meaningful clinical outcomes, regulatory interest and partnership activity are rising, catalyzed by precision patient-selection strategies, increasingly sensitive antigen-specific biomarker tools, and maturing delivery technologies. This event provides the only comprehensive forum to benchmark emerging modalities, share real-world clinical insights, and shape the next wave of targeted, durable, tolerance-inducing therapies.
The 2026 program is built to explore late-stage data from Diamyd, COUR, Topas Therapeutics, and Aravax, innovations in mRNA-LNP delivery, next-generation Treg and gene-edited cell therapies, breakthrough antigen-discovery platforms and so much more.
Attend the summit delivering the full-spectrum perspective needed to advance ASIT from concept to clinical proof and ultimately to meaningful, durable disease modification.
Unmissable 2026 Event Highlights
First Look at Late-Stage Data
Fresh data from leading programs including DIAGNODE-3 in type 1 diabetes from Diamyd, COUR's PBC and MG updates, Topas Therapeutics' celiac disease learnings and developments, and Aravax's late-phase II peanut-allergy trials.
Emerging Modalities Driving Tolerance
Deep dives into next-generation platforms from mRNA-LNP tolerance therapies to Treg and gene-edited cell therapies reflecting rapid innovation across peripheral and central tolerance strategies.
Breakthrough Antigen Discovery & Biomarker Innovation
Sessions exploring AI-enabled antigen prediction, TScan’s discovery platform, advanced tetramer-based assays, and next-generation biomarkers to identify responsive patient subsets, demonstrate proof-of-mechanism, and streamline clinical translation.
Practical Clinical & Regulatory Strategy
Highly applied discussions on trial design, potency assays, scaling cell therapy manufacturing, and regulatory expectations, equipping teams to bridge preclinical mechanistic signal to durable clinical benefit and commercial viability.
2026 Audience Composition
Attendee Seniority
Company Type
Explore the 2026 Full Event Guide
- Get a full overview of the agenda, speakers, and session topics in one place
- Share easily with your team to assess and mobilize interest
- Preview sessions containing brand-new data that we’ll be showcasing at the event
- Discover exclusive content from keynotes, academics, C-suite leaders, biotechs and biopharma executives
- Explore attendee benefits, exclusive event insights and anticipated audience metrics
Attending Companies Included
Explore the Agenda
Hear the latest ASIT industry breakthroughs and gain exclusive insights into the packed agenda, interactive roundtables, and panel discussions.
Partner With Us
Position yourself alongside leading drug developers and solution providers in this tight-knit community to ensure your brand is at the heart of the ASIT field.
Join Biopharma Experts
Be part of the hottest conversations with a specially curated audience of 60+ experts from like-minded attendees spanning all stages of drug development and make critical connections during our dedicated networking sessions.